Express News | NYSE Order Imbalance 591383.0 Shares on Sell Side
ReutersApr 26 15:50 ET
Express News | NYSE Order Imbalance 718960.0 Shares on Sell Side
ReutersApr 25 15:50 ET
Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes
08:31 AM EDT, 04/25/2024 (MT Newswires) -- Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes
MT NewswiresApr 25 08:31 ET
Express News | NYSE Order Imbalance 724291.0 Shares on Sell Side
Moomoo 24/7Apr 24 15:50 ET
FDA Approves Amneal's Generic Version of OTC Narcan
Seeking AlphaApr 24 11:01 ET
Express News | NYSE Order Imbalance 1047289.0 Shares on Sell Side
Moomoo 24/7Apr 23 15:50 ET
Bausch Health in 'Stronger Position' for Bausch + Lomb Distribution, RBC Says
Bausch Health (BHC) is in a "stronger position" to proceed with a Bausch + Lomb (BLCO) distribution to its shareholders following a recent appellate court ruling that prevents the Food and Drug Admini
MT NewswiresApr 23 12:04 ET
Bausch Health Price Target Cut to $11.00/Share From $12.00 by RBC Capital
Bausch Health Price Target Cut to $11.00/Share From $12.00 by RBC Capital
Dow JonesApr 23 11:55 ET
RBC Previews Bausch Health's Q1, Trims Target to US$11
Bausch Health will report Q1/24 results on May 2, one day after Bausch + Lomb's Q1 results. RBC estimates Q1/24 revenue of $2.13 billion (FactSet cons. $2.15 billion) and adj. EBITDA of $682 million (
MT NewswiresApr 23 11:18 ET
Analysts Conflicted on These Healthcare Names: Bausch Health Companies (BHC) and Enlivex (ENLV)
TipRanksApr 23 06:30 ET
Express News | Bausch Health Companies Inc : RBC Cuts Target Price to $11 From $12
Moomoo 24/7Apr 23 01:41 ET
RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1
Bausch + Lomb will report Q1/24 results BMO on May 1. RBC estimates (in US$) Q1/24 revenue of $1,069 million (cons. $1,063 million) and adj. EBITDA of $178 million (cons. ~$177 million). Q1/24 will co
MT NewswiresApr 22 12:41 ET
Bausch Health's Issuer Credit Rating Upgraded by SP
S&P Global Ratings said Thursday it upgraded the issuer credit rating on Bausch Health Cos. (BHC.TO) to CCC+ from CCC. Also, the rating agency upgraded the issue-level ratings on the senior secured de
MT NewswiresApr 19 11:25 ET
Fungal Keratitis Treatment Market Report 2024: Global Trends, Forecast and Competitive Analysis to 2030 Featuring Merck & Co, Bausch Health, Gilead Biosciences, Pfizer, and Glenmark Pharmaceuticals
Yahoo FinanceApr 19 09:24 ET
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Walgreens Boots Alliance (WBA) and Evolent Health (EVH)
TipRanksApr 15 07:20 ET
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says
Bausch Health (BHC) received a "positive" appellate court ruling on Xifaxan, though the market is assigning only a 32% chance of Bausch + Lomb (BLCO) distribution, RBC Capital Markets said Friday in a
MT NewswiresApr 12 12:31 ET
Express News | RBC Capital Reiterates Sector Perform on Bausch Health Companies, Maintains $12 Price Target
Moomoo 24/7Apr 12 10:15 ET
Bausch Health Companies Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/12/2024 36.75% RBC Capital → $12 Reiterates Sector Perform → Sector Perform 04/05/2024 36.75% RBC Capit
BenzingaApr 12 10:13 ET
RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds
RBC notes that Thursday's price movement on the TSX, for Bausch Health (+1%)/ Bausch + Lomb (-4%) suggests the market believes the probability of a BLCO distribution has declined following the positiv
MT NewswiresApr 12 08:46 ET
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Arcus Biosciences (RCUS)
TipRanksApr 12 06:50 ET
No Data
No Data